Anti-Hyperglycemic Properties of Crude Extract and Triterpenes  from Poria cocos by Li, Tzu-Hsuan et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 128402, 8 pages
doi:10.1155/2011/128402
Research Article
Anti-Hyperglycemic Properties of Crude Extract and Triterpenes
from Poriacocos
Tzu-HsuanLi,1,2 Chia-ChungHou,1 CiceroLee-TianChang,3 andWen-ChinYang1,2,4,5
1Agricultural Biotechnology Research Center, Academia Sinica Taipei 115, Taiwan
2Department and Institute of Pharmacology, National Yang-Ming University Taipei 112, Taiwan
3Department of Veterinary Medicine, National Chung Hsing University Taichung, Taiwan
4Institute of Zoology, National Taiwan University Taipei 10617, Taiwan
5Department of Life Sciences, National Chung Hsing University Taichung, Taiwan
Correspondence should be addressed to Cicero Lee-Tian Chang, ltchang@nchu.edu.tw
and Wen-Chin Yang, wcyang@gate.sinica.edu.tw
Received 1 April 2010; Accepted 7 August 2010
Copyright © 2011 Tzu-Hsuan Li et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Poria cocos, Bai Fu Ling in Chinese, is used in traditional Chinese medicine to treat diabetes. However, its claimed beneﬁts and
mechanism are not fully understood. This study aimed to investigate the eﬀect and action of P. cocos on type 2 diabetes. We ﬁrst
performed phytochemical analysis on the crude extract and factions of P. cocos. P. cocos crude extract at 50mg/kg body weight
or more signiﬁcantly decreased blood glucose levels in db/db mice. Based on a bioactivity-directed fractionation and isolation
(BDFI) strategy, chloroform fraction and subfractions 4 and 6 of the P. cocos crude extract possessed a blood glucose-lowering
eﬀect. Dehydrotumulosic acid, dehydrotrametenolic acid, and pachymic acid were identiﬁed from the chloroform sub-fractions
4, 3, and 2, respectively. Dehydrotumulosic acid had anti-hyperglycemic eﬀect to a greater extent than dehydrotrametenolic acid
andpachymic acid.Mechanistic studyonstreptozocin- (STZ-)treatedmice showedthatthecrudeextract,dehydrotumulosicacid,
dehydrotrametenolicacid,andpachymicacidofP. cocos exhibiteddiﬀerentlevelsofinsulinsensitizeractivity.However, the P. cocos
crude extract and triterpenes appeared not to activate PPAR-γ pathway. Overall, the data suggest that the P. cocos extract and its
triterpenes reduce postprandial blood glucose levels in db/db mice via enhanced insulin sensitivity irrespective of PPAR-γ.
1.Introduction
Diabetes mellitus is a life-threatening chronic metabolic
disease which currently aﬄicts 3% of the world population.
Over 90% of diabetic populations are diagnosed with
type 2 diabetes [1, 2]. Diabetes is caused by a defect in
insulin production, insulin action, or both [3]. The defect
impairs glucose homeostasis in diabetic patients, resulting
in hyperglycemia, a hallmark of diabetes [4]. Therefore,
one important method of treating patients with type 2
diabetes is to control blood glucose levels, which can be
achieved by an increase of insulin release (insulin releasers)
or insulin action (insulin sensitizers), a decrease of intestinal
glucose uptake (α-glucosidase inhibitors), and so forth [5].
However, few clinical drugs are available for diabetes, and
those that are available usually have adverse side eﬀects such
as decreased eﬃcacy over time and low cost-eﬀectiveness [6–
8]. Therefore, research and development of novel drugs for
diabetes have been in great demand.
P. cocos (Polyporaceae) is a rotten pine-tree fungus. It has
long been used as traditional Chinese medicine and food
[9–12]. P. cocos alone or in combination with other herbs
is often used to treat diabetes as well as other disorders
[13–15]. Several triterpenes, pachyman, and pachymaran
have been identiﬁed from P. cocos [16–19]. Dehydrotram-
etenolic acid, one triterpene constituent of P. cocos,w a s
shown to reduce hyperglycemia in db/db mice [20]. Besides,
dehydrotrametenolic acid was shown to activate peroxide
proliferator-activated receptor-γ (PPAR-γ), a regulator of
glucose metabolism, in the same way as the insulin sensitizer
ciglitazone [20]. However, this antidiabetic eﬀect and the
likely mechanism of P. cocos are still poorly studied.
In this study, we used db/db mice to evaluate the
glucose-lowering eﬀects of the crude extract, fractions,
and triterpenes of P. cocos. Based on a bioactivity-directed
fractionation and isolation (BDFI) procedure, triterpenes
from the crude extract of P. cocos were identiﬁed as active
compounds. Chromatography and spectroscopy were used2 Evidence-Based Complementary and Alternative Medicine
to characterize the phytochemistry of P. cocos. In addition,
STZ-treated mice were used to study the likely mechanism of
P. cocos and its active triterpenes.
2.MaterialsandMethods
2.1. Chemicals, Cells, and Plasmids. Dimethyl sulfoxide
(DMSO), glimepiride (GLM), metformin (Met), methanol,
ethyl acetate (EA), chloroform, acetonitrile (ACN), triﬂu-
oroacetic acid (TFA), and streptozocin (STZ) were pur-
chased from Sigma-Aldrich (MO, USA). Pachymic acid and
insulinwerepurchasedfromApinChemicalsLimited(Oxon,
UK) and Novo Nordisk (NJ, USA), respectively. 3T3-L1
a d i p o c y t e sw e r eg r o w ni nD M E Mm e d i u m( I n v i t r o g e n ,C A ,
USA) supplemented with 10% bovine calf serum (BCS),
100 units/mL penicillin, 100μg/mL streptomycin, 6mM
HEPES (Invitrogen, CA, USA), and 2mM L-glutamine
(Invitrogen) at 37
◦Ci n5 %C O 2. pSGGAL-PPAR-γ,w h i c h
expresses a chimeric protein of Gal4 DNA-binding domain
linked to PPAR-γ ligand-binding domain, and (UAS)5-tk-
LUC reporter construct, which contains a pentameric yeast
upstream activatory sequence linked to luciferase gene, were
generous gifts from Dr. Krister Bamberg (Astra Zeneca,
M¨ olndal, Sweden).
2.2. Preparation of Crude Extract, Fractions, and Triterpenes
of P. cocos. P. cocos was purchased from a local market in
Taipei, Taiwan. It was authenticated by the Development
Center for Biotechnology, Taiwan. Voucher specimens were
deposited at Agricultural Biotechnology Research Center. To
prepare methanol crude extract of P. cocos,d r i e dP. cocos was
ground into powder. P. cocos powder (5kg) was extracted
with methanol (1:10w/v) for 6 days three-times, yielding
7.5‰ methanol extract. The methanol crude extract was
dissolved in water (1L) and partitioned with chloroform
(1L × 5). After obtaining the chloroform fraction (0.82‰),
the rest of the extract was further partitioned with ethyl
acetate(1L×5),yieldinganethylacetatefraction(2.9‰)and
a water fraction (1.8‰). The active chloroform fraction was
further fractioned into chloroform sub-fractions 1 (0.10‰),
2 (0.11‰), 3 (0.11‰), 4 (0.12‰), 5 (0.10‰), and 6
(0.24‰) using a normal phase high-performance liquid
chromatography (HPLC) column (Phenomenex, Luna 5μ
silica, 250 × 1 0 m m )a taﬂ o wr a t eo f5 m l / m i n ,d e t e c t e d
with UV 242nm. The solvent gradient for HPLC is ethyl
acetate (a) and hexane (b): 0 to 60min: 30% A; 60 to 90min:
100% A. The 6 chloroform sub-fractions were chemically
characterized as published elsewhere [21] using an RP-C18
HPLC column (Phenomenex, Luna 5μ C18, 250 × 4.6mm)
at a ﬂow rate of 1ml/min, detected with UV 242nm.
The solvent gradient for HPLC is water/0.05% TFA (c)
and acetonitrile/0.05% TFA (d): 0 to 15min: 5 to 15%
D; 15 to 35min: 15 to 20% D; 35 to 65min: 20 to 40%
D; 65 to 100min: 40 to 100% D; 100 to 110min: 100%
D. Triterpenes were identiﬁed from the chloroform sub-
fractions using an RP HPLC column (Cosmosil, 5μ C18,
250 × 10mm) at a ﬂow rate of 5ml/min, detected with UV
242nm. The solvent gradient for HPLC was water/0.05%
TFA (e) and acetonitrile/0.05% TFA (f): 0 to 10min: 30
to 52% F; 10 to 50min: 52 to 100% F; 50 to 60min:
100% F. Dehydrotumulosic acid, dehydrotrametenolic acid,
and pachymic acid were identiﬁed by comparing the data
obtainedfromNMRandMSwiththosepublishedpreviously
in [21–23].
2.3. Animal and Drug Administration. Male C57BL/KsJ-
db/db mice, which possess a point mutation of the leptin
receptor, and male C57BL/6J mice were purchased from the
Jackson Laboratory (ME, USA) and the National Laboratory
Animal Center (Taipei, Taiwan), respectively. All animals
were housed and handled according to the guidelines of the
Academia Sinica Institutional Animal Care and Utilization
Committee.
Diabetic C57BL/KsJ-db/db mice aged between 6 to 8
weeks were denied food for 12h before the experiment and
then given free access to food and water for 2h. On time
0, food was removed (water accessible) and blood sampling
from this time point on was considered to be postprandial.
After grouping, mice were tube-fed with vehicle, metformin,
crude extract, fractions, sub-fractions, or compounds. Post-
prandial blood glucose level was monitored for 4h.
C57BL/6J mice aged 5 weeks were treated with an
intraperitoneal injection of STZ (200mg/kg). Mice with
postprandial blood glucose level over 500mg/dL and serum
insulin level below 0.18ng/ml were grouped and tube-fed
with control, metformin, glimepiride, crude extract, and
compounds (time−1h). Sixty minutes after tube-feeding of
mice, the mice were intraperitoneal injected with insulin at
2.5IU/kg BW (time 0). Blood glucose levels were measured
for 4h, and all the time points were given free access to food
and water. Blood glucose concentration was measured using
an Elite glucometer (Bayer, PA, USA). This experiment was
modiﬁed by previous studies [24, 25].
2.4. PPAR-γ Reporter Assay. 3T3-L1 (107) cells were elec-
troporated with pSGGAL-PPAR-γ and (UAS)5-tk-LUC at
260V and 975μF using a Bio-Rad electroporator (Bio-
Rad, Hercules, CA). Two hours after transfection, cells
were divided and treated with DMSO, rosiglitazone (RSG),
the crude extract, and triterpenes of P. cocos for 24h.
Ten μg of total lysates underwent dual luciferase assays as
published in [26]. PPAR-γ activity in folds was deﬁned as
the ﬁreﬂy/Renilla luciferase ratio normalized to the control
ﬁreﬂy/Renilla luciferase ratio.
2.5. Statistical Analysis. The results from three or more
independentexperimentswerepresentedasmean±S.E.Data
were analyzed by ANOVA. Bonferroni’s method was used for
post hoc comparisons when appropriate to determine the
source of signiﬁcant diﬀerences. Diﬀerences of P-value less
than .05 were considered statistically signiﬁcant.
3. Results
3.1. Phytochemical Analysis of Crude Extract, Fractions, Sub-
Fractions, and Triterpenes of P. cocos. P. cocos has been usedEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Isolation procedure and HPLC proﬁles of crude extract, fractions, sub-fractions, and triterpenes of P. cocos. (a) Flow chart of
preparation procedure of the crude extract, fractions, sub-fractions, and triterpenes of P. cocos. The yield of extract, fractions, sub-fractions,
andtriterpenesisindicatedinparentheses.(b)ChemicalproﬁlesofcrudeextractandfractionsofP.cocoswereobtainedusingHPLCcolumns
and detected with UV detectors. Dehydrotumulosic acid (DHTuA: 1), pachymic acid (PA: 2), and dehydrotrametenolic acid (DHTA: 3) were
identiﬁed from the Chl-4, Chl-2, and Chl-3 sub-fractions.
per se or together with other herbs as Chinese medicines
for diabetes [13]. However, its anti-diabetic eﬀect is poorly
understood. In this study, we ﬁrst chemically characterized
crude extract, fractions, and triterpenes of P. cocos based
on a BDFI procedure (Figure 1(a)). To prepare the crude
extract of P. cocos, its sclerotia were ground and extracted
by methanol. The methanol crude extract was further par-
titioned with water, ethyl acetate, and chloroform. The active
chloroform fraction was separated into 6 sub-fractions.
T h ec h l o r o f o r ms u b - f r a c t i o n s4a n d6w e r ea c t i v ea n do n e
triterpenes, dehydrotumulosic acid, was identiﬁed from the
active chloroform sub-fraction 4. Another two triterpenes,
pachymic acid and dehydrotrametenolic acid, were isolated
fromtheinactivechloroformsub-fractions2and3.Theyield
of the crude extract, fractions, sub-fractions, and triterpenes
of P. cocos is indicated in Figure 1(a). Their HPLC proﬁles
were determined as shown in Figure 1(b).
3.2. Glucose-Lowering Eﬀects of Crude Extract, Fractions,
Chloroform Sub-Fractions, and Triterpenes of P. cocos in db/db
Mice. Next, a mouse model of type 2 diabetes, db/db mice,
was used to evaluate the anti-diabetic potential of P. cocos.
First, we examined the glucose-lowering eﬀect of crude
extract of P. cocos in db/db mice. Diabetic db/db mice
aged 6 to 8 weeks spontaneously developed hyperglycemia,
and their postprandial blood glucose levels were somewhere
between 350 and 400mg/dL (Figure 2(a)). In contrast, the
levels of blood glucose in db/db mice receiving a dose of
control vehicle dropped to 165mg/dL over 4h (Figure 2(a)).
As expected, metformin signiﬁcantly lowered the levels of
blood glucose (Figure 2(a)) in db/db mice. Crude extract of
P. cocos at a single dose of 50 or 100mg/kg body weight also
signiﬁcantly reduced the blood glucose levels (Figure 2(a)).
Next, we tested the glucose-lowering eﬀect of the water,
ethyl acetate, and chloroform fractions of P. cocos on db/db
mice. The levels of blood glucose in mice receiving a
dose of control vehicle decreased to 164.5mg/dL over 4h
(Figure 2(b)). Metformin eﬀectively decreased the blood
glucose levels (Figure 2(b)). In contrast, the chloroform
fraction, but not the water and ethyl acetate fractions,
signiﬁcantly lowered blood glucose levels (Figure 2(b)).
Next, we further evaluated the glucose-lowering eﬀect of
chloroform sub-fractions 1–6, resulting from the active P.
cocos chloroform fraction. One dose of metformin eﬀec-
tively decreased the blood glucose levels in db/db mice as
compared to control vehicle. Chloroform sub-fractions 4
and 6 signiﬁcantly lowered the blood glucose levels to a
greater extent than the other 4 sub-fractions (Figure 2(c)).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Single-dose eﬀects of crude extract, fractions, sub-fractions, and triterpenes of P. cocos on the level of postprandial blood glucose
in db/db mice. (a) Diabetic db/db mice were tube-fed with water (Ctr), metformin (Met: 60mg/kg BW), and crude extract (CE: 10, 50
or 100mg/kg BW). Blood glucose levels were measured before (0h) and after (1 to 4h) tube feeding. (b) The same procedure as (a)
except that water (Ctr), metformin (Met: 60mg/kg BW), water fraction (Water: 50mg/kg BW), ethyl acetate fraction (EA: 50mg/kg BW),
and chloroform fraction (Chl, 50mg/kg BW) were administered. (c) The same procedure as (a) except that water (Ctr), metformin (Met:
60mg/kg BW), and 6 chloroform sub-fractions (Chl-1 to Chl-6: 50mg/kg BW) were administered. (d), The same procedure as (a) except
that DMSO/water (Ctr), metformin (Met: 60mg/kg), dehydrotumulosic acid (DHTuA: 1, 5, and 10mg/kg BW), pachymic acid (PA: 1, 5,
and 10mg/kg BW), and dehydrotrametenolic acid (DHTA: 1, 5, and 10mg/kg BW) were administered. All the above data are expressed as
mean ±S.E.P; (∗) less than .05 is considered to be statistically signiﬁcant. The mouse number (n) is indicated in parenthesis.
Thisloweringeﬀectofsub-fraction4(50mg/kgbodyweight)
seemed to last longer than that of sub-fraction 6 (50mg/kg
body weight) (Figure 2(c)).
Finally, we evaluated the glucose-lowering eﬀects of
triterpenes in db/db mice. Like metformin, dehydrotumu-
losic acid showed a signiﬁcant glucose-lowering activity in
db/db mice (Figure 2(d)). In contrast, dehydrotrametenolic
acid and pachymic acid, isolated from the less active chloro-
form sub-fraction 3 and 2, showed lower glucose-lowering
activities. However, we failed to identify active compounds
from the active chloroform sub-fraction 6 of P. cocos.
3.3. Mechanistic Study of the Crude Extract and Triterpenes
of P. cocos. Above we have shown that like metformin, P.
cocos and its triterpenes have diﬀerent hypoglycemic eﬀects
in db/db mice. To understand the anti-diabetic mechanism
of the crude extract of P. cocos and triterpenes, we examinedEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Glucose-lowering eﬀects of the crude extract of P. cocos and triterpenes in STZ-treated mice. C57BL mice, which have received a
high dose of STZ, were tube-fed with water (Ctr), glimepiride (GLM: 2.5mg/kg BW), metformin (Met: 60mg/kg BW), crude extract (CE:
10, 50, or 100mg/kg BW), dehydrotumulosic acid (DHTuA: 1, 5, or 10mg/kg BW), dehydrotrametenolic acid (DHTA: 1, 5, and 10mg/kg
BW), and pachymic acid (PA: 1, 5, or 10mg/kg). Blood glucose levels were measured before (−1 and 0h) and after (1 to 4h) tube feeding
and injection of insulin 2.5IU/kg BW. All the above data are expressed as mean ± S.E.P; (∗) indicates the diﬀerence between control (Ctr)
and experimental group. The mouse number (n) is indicated in parenthesis.
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Figure 4: Eﬀects of the P. cocos crude extract, dehydrotumulosic acid (DHTuA), and pachymic acid (PA) on PPAR-γ activation. (a) 3T3-L1
cells were transiently transfected with reporter constructs, pSGGAL4-PPAR-γ (2μg), and (UAS)5-tk-LUC plasmid (10μg). The cells were
treated with DMSO (N: negative control), rosiglitazone (RSG: 1μM), and the P. cocos crude extract (0.063, 0.25, and 0.63mg/ml). After 24h,
cell lysates were subjected to dual luciferase assay. (b) The same procedure as (a) except that the cells were treated with dehydrotumulosic
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their glucose-lowering eﬀects in STZ-treated mice whose β
islet cells were destroyed. Insulin administration was able
to decrease blood glucose levels in STZ mice (Figure 3).
As expected, glimepiride, an insulin releaser, had no eﬀect
on insulin-mediated blood glucose reduction in STZ-treated
mice(Figure 3).Incontrast,metformin,aninsulinsensitizer,
eﬀectively augmented the insulin-mediated blood glucose
reduction (Figure 3). In the same way as metformin, the
crudeextractofP.cocosalsoaugmentedtheinsulin-mediated
blood glucose reduction (Figure 3). Similar results were
obtained for dehydrotumulosic acid, dehydrotrametenolic
acidand,ifany,pachymicacid(Figure 3).Theseresultsimply6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: BDFI approach to study P. cocos and its active compounds for diabetes.
that P. cocos and triterpenes have the activities of insulin
sensitizer but not releaser.
PPAR-γ plays a role in glucose metabolism and is a target
of insulin sensitizing drugs. Therefore, we further examined
whetherthecrudeextractofP.cocosandtriterpenesregulated
PPAR-γ activation. As expected, rosiglitazone, a PPAR-γ
agonist, activated PPAR-γ (Figure 4). However, the crude
extract of P. cocos, dehydrotrametenolic acid, and pachymic
acid did not activate PPAR-γ (Figure 4). All the data suggest
that P. cocos and triterpenes reduce blood glucose level via an
enhancement of insulin sensitivity independent of PPAR-γ
(Figure 5).
4. Discussion
P. cocos is an edible fungus and is often used in various
Chinese herbal medicines [13]. One of its claimed beneﬁts
is to treat diabetes; however, the actual anti-diabetic eﬀects,
active constituent(s), and mode of action of P. cocos have
not been extensively studied. Here, we demonstrated, for the
ﬁrst time, that P. cocos shows an anti-diabetic eﬀect in db/db
mice as evidenced by its glucose-lowering activity (Figure 2).
Moreover, we showed, for the ﬁrst time, that dehydrotumu-
losic acid is one of the most eﬀective compounds present in
the crude extract of P. cocos (Figure 2). Dehydrotrametenolic
acid and, probably, pachymic acid were reported to be active
compounds of P. cocos for glucose reduction in db/db mice
[20]. Our data conﬁrmed that dehydrotrametenolic acid
and pachymic acid have lower glucose-reducing activities
than dehydrotumulosic acid (Figure 2(d)). The anti-diabetic
mechanism of P. cocos and its triterpenes are likely due to
their abilities to sensitize insulin-mediated glucose uptake
(Figure 3)[ 27]. Therefore, our ﬁndings provide insights into
the mechanism of action of P. cocos and its active triterpenes
against diabetes.
Lanostane-type triterpenes, pachymic acid, dehydro-
trametenolic acid, polyporenic acid C, dehydropachymic
acid and 3-O-acetyl-16α-hydroxy-dehydrotrametenolic acid,
and 3,4-secolanostane-type triterpenes, poricoic acid A, B,
and D were identiﬁed from P. cocos [20]. Among these
compounds, dehydrotrametenolic acid at 110mg/kg body
weight/day was conﬁrmed as an active triterpene against
hyperglycemia in db/db mice. In this paper, dehydrotumu-
losic acid was identiﬁed from P. cocos crude extract using
a bioactivity-directed fractionation and isolation strategy
(Figures 1 and 2). However, dehydrotrametenolic acid (in
chloroform sub-fraction 3) and pachymic acid (in chloro-
form sub-fraction 2) were not present in the active chlo-
roform sub-fractions 4 and 6 of P. cocos.T w or e a s o n sm a y
contribute to this contradiction. First, dehydrotrametenolic
acid and pachymic acid have lower bioactivities than dehy-
drotumulosic acid. Second, we found that the percentages
of dehydrotumulosic acid, dehydrotrametenolic acid, and
pachymic acid in P. cocos crude extract were 0.012‰,Evidence-Based Complementary and Alternative Medicine 7
0.0022‰and 0.053‰, respectively. The animal experiments
in db/db mice showed that dehydrotumulosic acid and
dehydrotrametenolic acid had higher anti-hyperglycemic
activity than pachymic acid (Figure 2(d)). Our data suggest
that triterpenes are the primary compounds present in the
crude extract of P. cocos despite their bioactivities with
diﬀerent degrees (Figures 1(a) and 2). Moreover, structures
of these 3 compounds were conﬁrmed by a comparison of
the NMR, MS, and UV spectroscopy data obtained with
published data from [21–23].
Crude extract of P. cocos and its triterpenes could reduce
blood glucose via increased insulin sensitivity, as evidenced
by STZ-treated mice (Figure 3). It is possible that the
increase in insulin sensitivity could be partially achieved by
modiﬁcation/activation of the PPAR- γ pathway. In fact, our
data showed that P. cocos and its triterpenes did not activate
PPAR- γ, a target of rosiglitazone (Figure 4). The mechanism
by which crude extract of P. cocos and its triterpenes exert
insulinsensitizeractivityisPPAR-γ independent.Biguanides
(e.g.,metformin)areanothertypeofinsulinsensitizer,which
activate 5  AMP-activated protein kinase. Whether or not
P. cocos and its triterpenes aﬀect 5  AMP-activated protein
kinase needs to be further studied [28].
Overall, db/db mice and STZ-treated mice experiments
showed that the crude extract and triterpenes dehydrotu-
mulosic acid and dehydrotrametenolic acid of P. cocos sig-
niﬁcantly enhanced the insulin sensitivity and, consequently,
lowered the blood glucose level in a diabetic mouse model.
This enhancement is independent of PPAR- γ activation.
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